Purple Biotech Ltd.
PPBTAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 26, 2024 |
| Chardan Capital | maintain | Buy | Mar 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 21, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 30, 2023 |
| Chardan Capital | maintain | Buy | May 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2023 |
| Chardan Capital | maintain | Buy | Feb 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 17, 2022 |
| Chardan Capital | maintain | Buy | Sep 8, 2022 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-2.88| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 7, 2026 | $1.07 | $-0.98 | — | — |
| May 15, 2026 | $-0.09 | $-3.80 | — | — |
| Mar 13, 2026 | $-19.85 | $-3.40 | — | — |
| Nov 14, 2025 | $-2.90 | $-2.60 | — | — |
| Aug 6, 2025 | $-4.00 | $-2.10 | — | — |
| May 21, 2025 | $-1.70 | — | — | — |
| Mar 10, 2025 | $-2.60 | $-2.20 | — | — |
| Nov 15, 2024 | $-13.70 | $-12.00 | — | — |
News
Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium …
REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands th…
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Purple Biotech (NASDAQ: PPBT - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Earnings and Valuation This table compares Ionis Pharmaceuticals